arrow
J

John M. Ssenkusu

School of Public Health
H指数:17
被引数:1,075

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction to: Correlates of virological non-suppression among children and adolescents aged 5–19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study

更正:乌干达北部古鲁地区转诊医院就诊的5-19岁儿童和青少年中,接受多替拉韦方案治疗的病毒学未抑制者的相关因素:一项混合方法横断面研究

2025-11-080
OAAI
Growth measurements in Ugandan children with sickle cell anaemia from a hydroxyurea (hydroxycarbamide) treatment trial relative to unaffected sibling controls

乌干达镰状细胞贫血儿童的生长测量结果,来自一项羟基脲(羟基脲)治疗试验,并与未受影响的同胞对照组进行比较

2025-10-060
PRE
Acceptability of immediate CPAP for preterm infants in the delivery room to mothers, caregivers and healthcare workers in a low-resource setting: a qualitative study

在资源有限环境下,对早产儿在分娩室立即使用CPAP的接受度:一项定性研究(针对母亲、照护者和医疗工作者)

2025-09-240
OAAI
Weekly dihydroartemisinin–piperaquine versus monthly sulfadoxine–pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial

乌干达和马拉维儿童镰状细胞贫血症疟疾化学预防中每周双氢青蒿素-哌喹与每月磺胺多辛-乙胺嘧啶的比较(CHEMCHA):一项随机、双盲、安慰剂对照试验

2024-12-200
OAAI
Neurocognitive Improvement with Hydroxyurea Therapy in Children with Sickle Cell Anemia in Uganda: Analysis from the Completed 30-Month BRAIN Safe II Trial

乌干达儿童镰状细胞贫血患者中羟基脲疗法的神经认知改善:已完成30个月BRAIN Safe II试验的分析

BLOOD
IF23.1
2024-11-050
PRE
Severe Malaria and Academic Achievement
2023-03-023
PRE